Articles On Resapp Health (ASX:RAP)

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is a sea of red and down heavily. At the time of writing, the benchmark index is down 4.25% to 6,634.7 points. Four ASX shares that have defied the odds and pushed higher are listed...

The S&P/ASX 200 (ASX: XJO) managed to reverse the prior day’s gains, falling 1% on Tuesday after US bond yields jumped on further central bank commentary. This coincided with agreement on further bans on Russian oil imports which sent t...

ShareCafeEvening Report: 31 May, 2022 by Melissa Darmawan   The Australian sharemarket closed at session lows, snapping its two-day winning streak as concerns mounted on hawkish comments from the Fed and whether the central bank can effecti...

Emerging markets index up 0.5% ASX200 1% lower Belararox (ASX:BRX) rocks    The ASX Emerging Companies (XEC) Index was trading 0.6% higher after lunch to the exact degree the ASX200 (XJO) was not, 0.6% weaker. At the close the small cap...

The ResApp Health Ltd (ASX: RAP) share price won’t be going anywhere on Tuesday. This comes as the company requested its shares be placed in a trading halt. At the time of writing, shares in the digital health company are frozen at 11 cent...

ShareCafeLunch Report: 31 May, 2022 by Melissa Darmawan   The Australian sharemarket takes a breather after two days of gains as resources stocks help offset the fall. The improvement in mobility in the world’s second largest economy provid...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

ResApp (RAP) reports increases in quarterly cash receipts and net cash outflows over the three months to March 31 2022 Company cash receipts jumped 44 per cent to $178,000 across the March quarter, with net cash outflows rising 62 per cent...

Judging from the hype of overly excited CEOs of even the earliest stage biotechs, cashed-up big pharma acquirers are queuing to make lucrative takeover offers for their (inevitably) unique and game-changing products and potions. The reality...

The Australian life sciences sector hasn’t had a good run in the past year. While the S&P/ASX 200 is up ~8%, the S&P/ASX 200 healthcare index has fallen ~2%.  However, Morgans senior analyst from the healthcare team Scott Power is c...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Highlights Investors are eyeing CSL as the company delivers a promising dividend consistently. SHL is under investors’ radar today as the company gained their trust by buying its own shares. RMD is soon to declare its Q3 FY22 results...

Pfizer has announced it will acquire ResApp Health (ASX:RAP) in an acquisition that values the Australian digital health company at $100 million.

It was another volatile day for the S&P/ASX 200 (ASX: XJO), with the market trading significantly higher before reversing gains to finish up just 0.1%. The ASX 200 and individual sectors continue to diverge on a daily basis as the press...

It’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XEC) index, (down 0.6%) gave up its early gains in a topsy-turvy Monday session. Just after the close, the XJO was weepingly flat – well, up 0...

Highlights The ASX Small Ordinaries index (ASX:XSO) surged 0.68% to 3,338 by 11:30 AM AEST today. 4DS, RAP and RNO are three penny stocks starting the week with a bang. Investors must do proper due diligence before investing in these...

Tiny HealthTech stock ResApp Health [ASX:RAP] is flying today. The share price is currently up 24.4% at the time of writing, thanks to a somewhat unexpected turn of events The post ResApp Shares Are Soaring 24% Higher Thanks to a Takeover B...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and has dropped into the red. At the time of writing, the benchmark index is down 0.1% to 7,471.9 points. Four ASX shares that are not letting that h...

ResApp gets takeover offer from Pfizer Recce gets Hong Kong patent RhinoMed comes out of trading halt and rallied 20% Smartphone-based health company ResApp Health (ASX:RAP) surprised the market this morning after revealing that global gi...

Pharmaceutical and biotech company Pfizer Australia offers to buy ResApp Health (RAP) for $100 million Under the proposal, Pfizer has proposed to acquire ResApp for 11.5 cents per share cash The offer price represents a 27.8 per cent premi...

ShareCafeWebinar Recap – MX1, SPL, MAP, RFL & RAP Catch up on the full webinar with presentations from Micro-X (ASX: MX1), Starpharma (ASX: SPL), Microba Life Sciences (ASX: MAP), RLF AgTech (ASX: RFL) & ResApp (ASX: RAP) Webinar R...

The ResApp Health Ltd (ASX: RAP) share price has exploded higher on Monday morning. At the time of writing, the digital health company’s shares are up a whopping 28% to 11.5 cents. Why is the ResApp share price rocketing higher? The ResApp...

The multinational providing one of the world's leading COVID-19 vaccines has struck a deal to acquire ResApp Health (ASX: RAP), a Brisbane-based company that has been on a long commercialisation road with its respiratory disease diagnosis t...

ShareCafeResApp (ASX: RAP) – Webinar Presentation Dr Tony Keating – CEO & MD – ResApp is developing the world’s first COVID-19 instant screening test that will use cough sounds to indicate the presence of a COVID-19 infection. ResApp (...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w...

Meditech specialist ResApp (RAP) strikes a one-year deal with a UK health trust to pilot its ResAppDx smartphone-based respiratory diagnostic test in four hospitals The ResApp tech, which is CE Marked in Europe and TGA-approved in Australi...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

ASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since February 22 Tuesday winners: ResApp (ASX:RAP), RiversGold (ASX:RGL)    The ASX Emerging Companies (XEC) index is 1.5% higher in late trade....

Highlights ResApp Health has achieved outstanding outcomes for its COVID-19 screening test that requires a smartphone. In a clinical trial, the smartphone-based screening test was found to correctly detect COVID-19 in 92% of people wit...

92% sensitivity for detecting COVID-19 with a new cough audio-based algorithm BRISBANE, Australia, March 22, 2022 /PRNewswire/ — ResApp Health Limited (ASX:RAP) today announced positive results for a new novel cough audio-based COVID-...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to record a strong gain. At the time of writing, the benchmark index is up 1.3% to 7,373.9 points. Four ASX shares that are climbing more than most today are listed below...

Highlights The ASX Small Ordinaries index was seen 0.49% up at 3,293.2, by 12:30 PM AEDT. RAP, RGL and NOX were three ASX penny stocks delivering high returns today. Making a consistent gain from penny stocks is not an easy task and i...

The ResApp Health Ltd (ASX: RAP) share price is shooting the lights out today. ResApp shares closed yesterday at 6.2 cents and are currently trading for 9.9 cents. That’s a whopping 59.7% gain for the ResApp share price in early morning tr...

ResApp Health (RAP) sees positive results from its smartphone-based COVID-19 screening test The company found its smartphone test detected COVID-19 in 92 per cent of people with the virus ResApp will now engage with regulators on the requ...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The Emerging Companies Index (XEC) climbed more than 2% higher on Thursday, before closing at 1.9%, while its benchmark colleague – the upmarket ASX 200 followed Wall Street’s ascendence, trading up a shade over 1% after the Fed lifted inte...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

ResApp Health (RAP) reports revenue of $80,900 for the half-year ending December 31, 2021, up 75 per cent from the prior corresponding period The company also witnessed losses go up 16 per cent to $3.63 million compared to $3.12 million as...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

ResApp Health (RAP) pens a two-year deal with an Australian aged care patient monitoring platform provider Through the non-exclusive agreement, Health Teams will use ResApps’s ResAppDx on both its telehealth platform and for in-room patien...

The S&P/ASX200 climbed into the close on Tuesday. Most of the 35 or so point gain (0.5%)  comes off the back of some good, steady central banking, delivered – nay, telegraphed – at 2.30pm when the Reserve Bank (RBA) left the cash rate a...

Key points Investors are responding positively to an update from Resapp today The company was awarded a patent in China UBS says the Chinese telehealth market is expected to reach US$54 billion by 2025 In the last year, the Resapp shar...

ResApp Health (RAP) has secured a patent in China for its cough analysis technology The company says the China National Intellectual Property Administration has accepted its patent application, which is owned by The University of Queenslan...

The ASX200 has vacillated all of Monday in a whiny, unattractive way for a major global index. Like a Kardashian (name one) unable to get out of bed, the heavyweight financial names and the major miners are just dragging everyone lower, dow...

As inflation sticks around and rate hikes come into play then volatility will pick up, the general consensus says. But volatility doesn’t mean a one way ticket into the red sea – it also means stocks can go back up after they slump. So it w...

Digital health company ResApp (RAP) saw its diagnostic technology integrated with Alodokter and Doctors on Demand over the December quarter ResApp is now live on telehealth platforms in Europe, Australia and Indonesia However, the main fo...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

ResApp Health (RAP) has seen its acute respiratory diagnostic test go live with Doctors on Demand in Australia The digital health company reported its acute respiratory diagnostic test, ResAppDx, has been implemented into the Doctors on De...

ResApp Health’s (RAP) smartphone diagnostic test is set to launch in the Philippines through an agreement with telehealth company Homify Homify was founded last year and plans to launch with ResApp’s smartphone-based acute respiratory diag...

Local stocks made a cautious start to the week, following a fairly volatile trading period last week as jitters stemming from rising bond yields dimmed risk sentiment on global markets. The ASX 200 opened in the red before clawing back some...